WCLC 2022 | Response to systemic anti-cancer therapy in uncommon EGFR mutations

Hazel O’Sullivan, MBBS, The Royal Marsden NHS Foundation Trust, London, UK, provides an overview of a retrospective analysis of patients with uncommon EGFR mutations treated with systemic anti-cancer therapy. The study revealed patients who were treated with a first-line tyrosine kinase inhibitor (TKI) achieved a response rate of over 40%. The response rate was higher in patients with a compound EGFR mutation. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.